Page 43 - IB January 2022

We want to run this ad in the January issue and online.
It is to get someone to help Sam on the editorial side so
Islands Business is looking for an editor.
Sam can do some more work on the business develop-
ment side.

ISLANDS BUSINESS

www.islandsbusiness.com December 2021 FJD $8
IS LOOKING FOR AN EDITOR.

Do you have deep experience reporting on our region and a good understanding of the
political, economic and social issues facing the Pacific islands? Islands Business is recruiting
PERSON THEYEAR
OF
an editor to join our team.
FIAME + UNAISI VUNIWAQA
You will be experienced at commissioning articles, photography and illustrations, editing copy, fact-checking
and managing multiple deadlines. You will also be responsible for researching and producing content for our
magazine and online channels.

Islands Business magazine publishes monthly, online and in print. We also have a stand-alone news website. In
this role you will be responsible for working with our experienced cohort of freelance journalists, photographers
and designers across the region, and with our Fiji-based team.

We offer flexible working arrangements as long as deadlines are met. You can be based anywhere in the Pacific
Islands with a good internet connection, although some travel will (eventually) be required.

If you are interested in this role, please send an application letter and a copy of your CV, with links to examples
of your work to editor@islandsbusiness.com

Applications close February 14, 2022.

TRADE MARK CAUTIONARY NOTICE IN MICRONESIA, MARSHALL ISLANDS, PALAU, COOK ISLANDS AND TIMOR-LESTE
Notice is hereby given that ModernaTX, Inc., of 200 Technology Square, 2nd Floor, Cambridge MA 02139, United States of America is the sole
proprietor in Micronesia, Marshall Islands, Palau, Cook Islands and Timor-Leste of the following trade mark:
MODERNA

Used in respect of
Class 1: Biochemicals, namely, protein-encoding nucleic acids and polypeptide-encoding nucleic acids for in vivo, ex vivo, on vivo or in vitro scientific
research and medical research, and for use in the manufacture of food or nutritional supplement; biochemicals, namely, protein-encoding nucleic acids
and polypeptide-encoding nucleic acids for use in the manufacture of pharmaceuticals for treating cancers, neurological disorders, cardiovascular
disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; reagents for
testing sterility of pharmaceuticals; diagnostic reagents for scientific or research use; chemicals for use in biotherapeutics, biosimilars and therapeutics
product development and manufacturing processes; polypeptide encoding nucleic acids for laboratory use.
Class 5: Medical, biological and pharmaceutical preparations for scientific, research, medical, or pharmaceutical use, namely, preparations for treating
cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious
disorders, and reproductive disorders; medical, biological and pharmaceutical preparations containing polypeptide encoding nucleic acids for the
prevention and treatment of rare diseases, cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory
disorders, metabolic disorders, infectious disorders and reproductive disorders; RNA-based therapeutics and therapeutic agents for in vitro preparation
and in vivo, ex vivo, or on vivo delivery to cell sites; medical diagnostic reagents; pharmaceuticals, vaccines, medicines, biologics, biotherapeutics,
biosimilars and therapeutics.
Class 42: Scientific research in the fields of pharmaceuticals, vaccines, medicine, biologics, biotherapeutics, biosimilars and therapeutics; design,
engineering, research, development and testing services in the field of protein-encoding nucleic acids and polypeptide-encoding nucleic acids.
The proprietor claims all rights in respect of the above trade mark and will take all necessary legal steps against any person or company infringing
their said rights.
DAVIES COLLISON CAVE PTY LTD
1 Nicholson Street, Melbourne VIC 3000, Australia
Telephone: +61 3 9254 2777; Facsimile: +61 3 9254 2770
Email: nholmes@dcc.com

Islands Business, January 2022 43